Back to search
FDAFDA · Food and drugs·Recall number D-0764-2022

SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02.

Published April 13, 2022 · Recall initiated: March 21, 2022

Summary

FDA records drug Class I recall D-0764-2022, published April 13, 2022 and initiated March 21, 2022. Recalling firm: Adamis Pharmaceuticals Corporation; Status: Terminated; Reported quantity: 2,500 cartons; Lot: Lot # 21101Y, Exp. 11/30/2022. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Adamis Pharmaceuticals Corporation
Distributor
Nationwide in the U.S.A.
Lot
Lot # 21101Y, Exp. 11/30/2022
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was SYMJEPI (epinephrine injection, USP) 0.15 mg (0.15 mg/0.3 mL), Two Pre-Filled Single-Dose Syringes per carton, Rx Only, Manufactured for Adamis Pharmaceuticals Corp.; San Diego, CA 92130; Distributed by USWM, LLC., Louisville, KY 40241, Made in Belgium, NDC 78670-131-02. recalled?

Yes. FDA published recall D-0764-2022 on April 13, 2022. Reported hazard: Defective Delivery System: Potential clogging of the needle preventing the dispensing of epinephrine.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit